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Table I. Cutaneous side effects of capecitabine
Lichenoid stomatitis Lichenoid lesions associated with bullous areas on anterior
tongue and erythema on bilateral buccal cheeks.4
Nail and periungual toxicity Changes may affect the nail matrix, nail bed, and proximal nail
fold e subungual hyperkeratosis, onycholysis,
onychomadesis,1 acute paronychia, exudative discharge from
nails, and erythematous papular, and vascular lesions in nail
folds.5
Palmar-plantar erythrodysesthesia (hand-foot syndrome) Most common cutaneous reaction to capecitabine, resulting in
tingling sensation of palms and soles, followed by burning 3
to 4 days later with swelling and erythema, possibly leading
to ulceration of the skin.2
Subacute cutaneous lupus erythematosus Erythematous, nonscarring papulosquamous or annular lesions
distributed over photosensitive areas.
Other common dermatologic conditions Can induce dermatitis with pruritus, bullous eruptions, xerosis,
and alopecia. It may also cause inflammation of preexisting
actinic keratosis.3
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To the Editor: Amicrobial pustulosis of the skin folds
(APF) is a rare clinical condition, often associated
with autoimmune disorders and characterized by
relapsing pustular eruptions affecting the skin folds.
Conventional treatment is based on systemic ste-
roids.1 However, relapses of the disease following
tapering or discontinuation of steroids are common.
Here we present the case of resistant APF success-
fully treated with anakinra.
A 48-year-old woman was followed for sys-
temic lupus disease since 1997; she was in
remission on low-dose prednisone and hydroxy-
chloroquine. In 2010, she presented with pustules
and exudative crust plaques in folds. Lesional
swabs were negative and skin biopsy showedOpen access under CC BY-NC-ND license.spongiform pustules in the epidermis with neutro-
philic infiltrate. APF was suspected and the patient
was first treated with dapsone without resolution.
An inflammatory bowel disease developed with
neutrophilic infiltrate seen on gut histology.
Because of the gastrointestinal (GI) tract involve-
ment, anti-tumor necrosis factor (anti-TNF)-
therapy (infliximab 5 mg/kg) was initiated along
with prednisone (35 mg/day), with initial resolu-
tion of GI and skin symptoms. However, the skin
disease flared when the prednisone was tapered
to 25 mg/day, despite continuation of infliximab.
After 15 anti-TNF- infusions without improve-
ment, infliximab was switched to ustekinumab.
The patient’s skin lesions continued to flare every
time systemic steroid therapy dose was reduced,
leading to cushingoid side effects. Because of the
dependence of APF on systemic steroids and
because of its resistance to biologic therapies,
we assessed the expression level of several pro-
and anti-inflammatory-related genes in lesional
and nonlesional skin biopsies. IL-1, IL-6, IL-2
receptor (IL-2R), and IL-7R gene expression were
elevated in lesional skin, suggesting increased
cutaneous inflammation and T-cell expansion
(Table I). Therefore, the increased expression of
the cytokine IL-1, a major mediator of cutaneous
inflammation,2 prompted us to prescribe ‘‘off-
label’’ anakinra (IL-1 receptor antagonist), which
blocks either IL-1 or IL-1 activity. After 1 month
of therapy, the patient’s lesions cleared (Fig 1).
After 1 year of follow-up, the patient’s skin
condition was still in remission on anakinra
therapy.
The pathogenesis of APF and its relationship
with the underlying autoimmune disease remain
Table I. Gene expression profile obtained from lesional and nonlesional skin of patient
Gene Symbol Description Lesional/Nonlesional
CBLB Cas-Br-M (murine) ecotropic retroviral transforming sequence b D
CD40 CD40 molecule (TNF receptor superfamily member 5) D
CDK2 Cyclin-dependent kinase 2 D
CMA1 Chymase 1, mast cell D
CSF1 Colony stimulating factor 1 (macrophage) D
CTLA4 Cytotoxic T-lymphocyte-associated protein 4 U
DGKA Diacylglycerol kinase, alpha 80 kDa D
DGKZ Diacylglycerol kinase, zeta 104 kDa D
EGR2 Early growth response 2 D
EGR3 Early growth response 3 D
EOMES Eomesodermin homolog D
FAS Fas (TNF receptor superfamily, member 6) U
FOXP1 Forkhead box P1 D
FOXP2 Forkhead box P2 D
GATA3 GATA binding protein 3 D
GZMB Granzyme B U
ICAM1 Intercellular adhesion molecule 1 U
IL10RA Interleukin 10 receptor, alpha U
IL1A Interleukin 1, alpha U
IL2RA Interleukin 2 receptor, alpha U
IL6 Interleukin 6 U
IL7R Interleukin 7 receptor U
ING4 Inhibitor of growth family, member 4 D
JAK1 Janus kinase 1 D
JAK3 Janus kinase 3 U
LEP Leptin D
LGALS3 Lectin, galactoside-binding, soluble, 3 D
LTA Lymphotoxin alpha (TNF superfamily, member 1) D
MEF2A Myocyte enhancer factor 2A D
NFATC1 Nuclear factor of activated T-cells, cytoplasmic, calcineurin-dependent 1 D
NFATC2 Nuclear factor of activated T-cells, cytoplasmic, calcineurin-dependent 2 D
NFATC3 Nuclear factor of activated T-cells, cytoplasmic, calcineurin-dependent 3 D
NHLH2 Nescient helix loop helix 2 D
NOTCH1 Notch homolog 1, translocation-associated D
PTGS2 Prostaglandin-endoperoxide synthase 2 U
RNF128 Ring finger protein 128 D
TNFRSF18 Tumor necrosis factor receptor superfamily, member 18 D
TNFRSF8 Tumor necrosis factor receptor superfamily, member 8 U
TNFSF8 Tumor necrosis factor (ligand) superfamily, member 8 U
Transcriptomic analysis of lesional (L) and nonlesional (NL) skin of patient was performed using Human T-cell Anergy and Immune Tolerance
PCR Array (Qiagen). The modulation is expressed as the ratio of signal intensities for lesional skin over nonlesional skin. Arbitrarily, only
modulation greater than 2 was considered significant.
D, Downregulation; U, upregulation.
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matoses, APF can also be complicated by the
development of extracutaneous neutrophilic clin-
ical features.3 Therefore, GI tract symptoms in our
patient could be considered a clinical feature
associated with APF. Therapy for APF is not well
standardized and the use of biologic therapies has
not been reported so far.4 However the failure of
APF to respond to conventional and biologic
therapies led us to define the immune responsein lesional skin using gene expression profile
analysis. The increased expression of IL-1
prompted us to block this cytokine using ana-
kinra, which led to complete remission. A previ-
ous study showed a high level of IL- 1 in lesional
skin in a pediatric case of APF, reinforcing our
presented data.5 Our case illustrates the benefit of
using basic science research to better define
the inflammatory profile of difficult to treat skin
diseases.
Fig 1. Amicrobial pustulosis of the skin folds. Clinical features of the patient before anakinra
therapy (left) and 1 month (right) after beginning treatment.
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